University of Calgary-born Parvus Therapeutics has inked an $800m deal with Genentech to develop and commercialise treatments for autoimmune diseases.

Parvus Therapeutics, a Canada-based biopharmaceutical spinout of University of Calgary, has signed a collaboration and licensing deal with biotechnology developer Genentech worth more than $800m. The two companies will work together on the development, manufacturing and commercialisation of treatments based on Parvus’ Navacim platform. They will focus on inflammatory bowel disease, autoimmune liver diseases and…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.